Premium
A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil
Author(s) -
Girdler N. M.,
Lyne J. P.,
Wallace R.,
Neave N.,
Scholey A.,
Wesnes K. A.,
Herman C.
Publication year - 2002
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1046/j.1365-2044.2002.02785.x
Subject(s) - medicine , sedation , flumazenil , midazolam , anesthesia , sedative , psychomotor learning , adverse effect , crossover study , hypnotic , randomized controlled trial , cognition , benzodiazepine , surgery , placebo , pharmacology , psychiatry , receptor , alternative medicine , pathology
Summary Flumazenil is traditionally administered intravenously to reverse the adverse effects of over sedation with benzodiazepines. The aim of this study was to test postoperative cognitive and psychomotor recovery from midazolam conscious sedation, following reversal with orally administered flumazenil. It was hypothesised that when administered by the oral route, flumazenil may enhance recovery over a prolonged period, thus increasing safety. Eighteen patients requiring intravenous midazolam sedation for dental treatment completed a randomised, double‐blind, crossover trial. Following treatment the patients' sedation was reversed using either flumazenil or saline (asplacebo), administered orally, on alternate appointments. Assessment of mood and cognitive function were undertaken using ClinPhone.cdr®, a highly sensitive and specific computerised battery of cognitive tests administered by telephone prior to sedation and every hour for seven hours post reversal. Results indicate that within 20 min of administration, oral flumazenil is capable of partially reversing some cognitive and psychomotor impairments but the attentional and stimulus discrimination effects of midazolam sedation still remain.